Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
09.11.Ramaswamy's biotech baggage haunted his political run
09.11.State incentives for commercial-stage life sciences companies
09.11.Translating Phase II success into Phase III readiness takes more than scale
09.11.Making the 'impossible' executable in life sciences construction
06.11.Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
06.11.Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
06.11.This week in charts: 3 drug launches Wall Street is watching
05.11.Medicare will cut billions from 340B, expand site-neutral payments in 2027
05.11.At ASH, drugmakers to showcase early data for three-pronged cancer therapies
05.11.Revolution's Rasonque off to best cancer drug launch 'in history'
05.11.T-Therapeutics reloads with a $133M megaround for bispecifics
05.11.Alethio raises $90M to target rare blood cancers
04.11.Sanofi stops development of Nurix-partnered immune drug
04.11.Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
04.11.CVS to split into two companies in stunning strategic about-face
04.11.Biopharma likely to climb higher after 'blue wave,' analysts say
03.11.Vertex, ahead of FDA decision, calms fears surrounding kidney drug
03.11.UniQure gets an FDA decision date; Teva scraps brain drug study
03.11.Medicare Part D premiums are spiking 50% on average next year, KFF finds
02.11.Karyopharm, deep in debt, to sell itself in bankruptcy
02.11.Keytruda biosimilars are coming - but they face an uphill battle
02.11.Earnings roundup: AstraZeneca's cost cuts, Alnylam's slump and Regeneron's resilience
02.11.Breaking the silos: What effective scenario modeling looks like in 2026 and beyond
30.10.This week in charts: ESMO's winners and losers
30.10.With Setara, the team behind Actio opens its second act